Ulcers is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Ulcers have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Ulcers compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ulcers overview
Ulcers refer to open sores that develop on the mucous membranes of the body. Peptic ulcers specifically affect the stomach (gastric ulcers) or the upper part of the small intestine (duodenal ulcers). The most common cause of peptic ulcers is infection with Helicobacter pylori bacteria or long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs). Symptoms may include abdominal pain, bloating, nausea, and vomiting. Diagnosis involves endoscopy and other imaging techniques. Treatment often includes medications to reduce stomach acid production, antibiotics to eradicate H. pylori, and lifestyle changes. In severe cases, surgery may be necessary. Prompt diagnosis and appropriate management are crucial for preventing complications.
For a complete picture of PTSR and LoA scores for drugs in Ulcers, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
